Search results for "Sirolimus therapy"

showing 1 items of 1 documents

2019

PIK3CA-related overgrowth spectrum (PROS) encompasses a range of debilitating conditions defined by asymmetric overgrowth caused by mosaic activating PIK3CA variants. PIK3CA encodes the p110α catalytic subunit of phosphatidylinositol-3-kinase (PI3K), a critical transducer of growth factor signaling. As mTOR mediates the growth-promoting actions of PI3K, we hypothesized that the mTOR inhibitor sirolimus would slow pathological overgrowth. Thirty-nine participants with PROS and progressive overgrowth were enrolled into open-label studies across three centers, and results were pooled. For the primary outcome, tissue volumes at affected and unaffected sites were measured by dual energy X-ray ab…

0301 basic medicinemedicine.medical_specialtybusiness.industrySirolimus therapyLow doseDiscovery and development of mTOR inhibitorsGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicinePrimary outcome030220 oncology & carcinogenesisSirolimusInternal medicinemedicineAsymmetric overgrowthbusinessAdverse effectPathologicalGenetics (clinical)medicine.drugGenetics in Medicine
researchProduct